Entasis Announces $50 Million Series B Financing led by Clarus
Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced the completion of a $50 million Series B financing to advance its pipeline of clinical and preclinical products. The financing was led by Clarus and included Frazier Healthcare Partners, Novo A/S, and Eventide Funds, who joined founding investor AstraZeneca.